One of our largest positions on the taxable bond side has been with FS Credit Opportunities (NYSE:FSCO), a relatively new listed closed-end fund (“CEF”)
Thesis Based on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s imminent catalysts (Reproxalap), considering the company holds $133 million in cash, cash equivalents and marketable securities, as